Drug Guidance for Subsidy 03/05/2017 Sumatriptan for the treatment of acute migraine attacks Following an evaluation of sumatriptan for the treatment of acute migraine attacks, sumatriptan 50mg... See all × 03/05/2017 Sumatriptan for the treatment of acute migraine attacks Following an evaluation of sumatriptan for the treatment of acute migraine attacks, sumatriptan 50mg tablet is recommended for listing on the MOH Standard Drug List (SDL) by the MOH Drug Advisory Committee in view of its clinically superior outcomes when used in combination with naproxen compared with either sumatriptan or naproxen monotherapy, and the low cost of subsidy. RThis recommendation means that subsidies will apply to sumatriptan for the indications registered in Singapore: Acute relief of migraine attacks with or without aura, including the acute treatment of migraine attacks associated with the menstrual period in women.
General Availability in Public Healthcare Institution Users are to consult the respective PHIs for actual inventory availability and supply restrictions/consideration Tablet 50 mg Alexandra Hospital Changi General Hospital KK Women's and Children's Hospital Khoo Teck Puat Hospital National Healthcare Group Polyclinics Ng Teng Fong General Hospital National University Hospital National University Polyclinics Sengkang General Hospital Singapore General Hospital SingHealth Polyclinics Tan Tock Seng Hospital Woodlands Health Campus Injection 6 mg/0.5 mL Ng Teng Fong General Hospital
ORAL Select a brand starting with the letter: I S IMIGRAN TABLET 50 MG [SIN08419P] SUMATRAN TABLET 50MG [SIN13667P]